STOCK TITAN

CytoSorbents to Report Q1 2021 Operating and Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

CytoSorbents Corporation (NASDAQ: CTSO) will announce its Q1 2021 financial results on May 4, 2021, at 4:45 PM EST. The company specializes in blood purification technology, notably CytoSorb®, aimed at managing inflammation in critically ill patients. A live conference call will follow the results announcement, providing insights into operational and financial progress. CytoSorbents' technology has been utilized in over 121,000 treatments and is approved in the EU for various applications, including COVID-19 management.

Positive
  • CytoSorbents has conducted over 121,000 human treatments with CytoSorb technology.
  • CytoSorb® is approved in the EU and distributed in 67 countries.
  • The company has received more than $38 million in funding from reputable government entities.
Negative
  • None.

MONMOUTH JUNCTION, N.J., April 27, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q1 2021 financial results after the market close on Tuesday, May 4, 2021 at 4:45PM EST

CytoSorbents Corporation to Report Q1 2021 Operating and Financial Results on Tuesday, May 4, 2021

CytoSorbents' management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q1 2021 followed by a question and answer session.

Conference Call Details:

Date:

Tuesday, May 4, 2021

Time:

4:45 PM Eastern

Toll Free:

877-451-6152

International:

201-389-0879

Conference ID:

13718834

Live Presentation Webcast:

http://public.viavid.com/index.php?id=144427

It is recommended that participants dial in approximately 10 minutes prior to the start of the call.  There will also be a simultaneous live webcast of the conference call that can be accessed through the following audio feed link: http://public.viavid.com/index.php?id=144427

An archived recording of the conference call will be available under the Investor Relations section of the Company's website at http://cytosorbents.com/investor-relations/financial-results/ 

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution  in 67 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used in more than 121,000 human treatments to date. CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma), and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances. CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $38 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including ECOS-300CY™, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ™, K+ontrol™, DrugSorb™, ContrastSorb, and others. For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our ability to leverage designation of CytoSorb as a breakthrough device under the FDA's  Breakthrough Devices Program in order to expedite the development, assessment, and regulatory review of CytoSorb, as well as the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2021, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements, particularly in light of the current coronavirus pandemic, where businesses can be impacted by rapidly changing state and federal regulations, as well as the health and availability of their workforce. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws. 

Please Click to Follow Us on Facebook and Twitter

CytoSorbents Contact: 
Amy Vogel
(732) 398-5394
avogel@cytosorbents.com

Public Relations Contact:
Eric Kim 
Rubenstein Public Relations
212-805-3052
ekim@rubensteinpr.com  

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cytosorbents-to-report-q1-2021-operating-and-financial-results-301278274.html

SOURCE CytoSorbents Corporation

FAQ

When will CytoSorbents report Q1 2021 financial results?

CytoSorbents will report Q1 2021 financial results on May 4, 2021, at 4:45 PM EST.

What is the focus of CytoSorbents' technology?

CytoSorbents specializes in blood purification to treat inflammation in critically ill patients.

How many treatments have been conducted using CytoSorb technology?

CytoSorb technology has been utilized in over 121,000 human treatments.

In how many countries is CytoSorb approved and distributed?

CytoSorb is approved and distributed in 67 countries worldwide.

Cytosorbents Corp.

NASDAQ:CTSO

CTSO Rankings

CTSO Latest News

CTSO Stock Data

49.21M
52.59M
3.82%
33.46%
2.49%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
PRINCETON